Back to Search
Start Over
Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies.
- Source :
-
Leukemia [Leukemia] 2014 Apr; Vol. 28 (4), pp. 941-4. Date of Electronic Publication: 2013 Oct 23. - Publication Year :
- 2014
- Subjects :
- Administration, Oral
Cycloparaffins pharmacology
HEK293 Cells
Hep G2 Cells
Humans
Ketones pharmacology
Protein Kinase Inhibitors pharmacology
Cycloparaffins therapeutic use
Janus Kinase 3 antagonists & inhibitors
Ketones therapeutic use
Lymphoma, T-Cell drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Protein Kinase Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5551
- Volume :
- 28
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Leukemia
- Publication Type :
- Report
- Accession number :
- 24153015
- Full Text :
- https://doi.org/10.1038/leu.2013.309